AAAAAA

   
Results: 1-22 |
Results: 22
HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME
Authors: WALLIS DE LEWIS BE MESSMORE H WEHRMACHER WH
Citation: De. Wallis et al., HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME, Clinical and applied thrombosis/hemostasis, 4(3), 1998, pp. 160-163
HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES
Authors: FAREED D FAREED J YANG L HOPPENSTEADT D JESKE W HAAS S MESSMORE H
Citation: D. Fareed et al., HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES, The FASEB journal, 12(4), 1998, pp. 1117-1117
HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES
Authors: FAREED D FAREED J YANG L HOPPENSTEADT D JESKE W HAAS S MESSMORE H
Citation: D. Fareed et al., HIRUDIN DOES NOT PREVENT PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIC SYNDROMES, Journal of the American College of Cardiology, 31(2), 1998, pp. 24-24
THROMBOPHILIA - CONSIDER HOMOCYSTEINE TOO
Authors: WEHRMACHER WH MESSMORE H
Citation: Wh. Wehrmacher et H. Messmore, THROMBOPHILIA - CONSIDER HOMOCYSTEINE TOO, Clinical and applied thrombosis/hemostasis, 3(2), 1997, pp. 147-148
COMPARATIVE-STUDIES ON THE BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIESOF A MAJOR METABOLITE OF ARGATROBAN (M1) - POTENTIAL CLINICAL IMPLICATIONS
Authors: AHSAN A AHMAD S IQBAL O SCHWARZ R KNAPPENBERGER G JOFFRION J BECKER JC MESSMORE H
Citation: A. Ahsan et al., COMPARATIVE-STUDIES ON THE BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIESOF A MAJOR METABOLITE OF ARGATROBAN (M1) - POTENTIAL CLINICAL IMPLICATIONS, Thrombosis and haemostasis, 1997, pp. 370-370
FIBRINOGEN ASSAY IN PLASMA UTILIZING BOTHROPS ATROX VENOM
Authors: MESSMORE H SUNG G FARID S IQBAL O FABBRINI N
Citation: H. Messmore et al., FIBRINOGEN ASSAY IN PLASMA UTILIZING BOTHROPS ATROX VENOM, Thrombosis and haemostasis, 1997, pp. 1788-1788
PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN IN PATIENTS UNDERGOING ANTICOAGULANT TREATMENT AND CORONARY ANGIOPLASTY
Authors: AHMAD S AHSAN A GEORGE M WYMA D SCHWARZ R KNAPPENBERGER G JOFFRION J BECKER JC MESSMORE H
Citation: S. Ahmad et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN IN PATIENTS UNDERGOING ANTICOAGULANT TREATMENT AND CORONARY ANGIOPLASTY, Thrombosis and haemostasis, 1997, pp. 2412-2412
HYPERVISCOSITY AND COAGULOPATHY DUE TO CIRCULATING HYALURONIC-ACID INA PATIENT WITH HEPATOMA
Authors: MESSMORE H ORFEI E COYNE E FRESCO R FAREED J
Citation: H. Messmore et al., HYPERVISCOSITY AND COAGULOPATHY DUE TO CIRCULATING HYALURONIC-ACID INA PATIENT WITH HEPATOMA, Blood, 90(10), 1997, pp. 3190-3190
SUCCESSFUL TREATMENT OF HEPARIN-ASSOCIATED THROMBOCYTOPENIA AND THROMBOSIS USING HIRULOG
Authors: CHAMBERLIN JR LEWIS B LEYA F WALLIS D MESSMORE H HOPPENSTEADT D WALENGA JM MORAN S FAREED J MCKIERNAN T
Citation: Jr. Chamberlin et al., SUCCESSFUL TREATMENT OF HEPARIN-ASSOCIATED THROMBOCYTOPENIA AND THROMBOSIS USING HIRULOG, Canadian journal of cardiology, 11(6), 1995, pp. 511-514
PERFORMANCE-CHARACTERISTICS OF THE MORE RESPONSIVE THROMBOPLASTIN REAGENTS
Authors: FABBRINI N HEMPHILL S GODWIN J MESSMORE H BALBALE S LAY M PANZA L CROSBY T DILLON R BRACE L
Citation: N. Fabbrini et al., PERFORMANCE-CHARACTERISTICS OF THE MORE RESPONSIVE THROMBOPLASTIN REAGENTS, Thrombosis and haemostasis, 73(6), 1995, pp. 1113-1113
COMPARISON OF THE PERFORMANCE-CHARACTERISTICS OF 14 COMMERCIAL PARTIAL THROMBOPLASTIN REAGENTS
Authors: FABBRINI N MESSMORE H BRACE L HEMPHILL S BALBALE S LAY M PANZA L CROSBY T DILLON R GODWIN J CHEIFEC G
Citation: N. Fabbrini et al., COMPARISON OF THE PERFORMANCE-CHARACTERISTICS OF 14 COMMERCIAL PARTIAL THROMBOPLASTIN REAGENTS, Thrombosis and haemostasis, 73(6), 1995, pp. 1238-1238
FISH SKIN GLYCOSAMINOGLYCANS - A SOURCE FOR HIGHLY-ACTIVE HEAVILY SULFATED CHONDROITIN SULFATES
Authors: COYNE E MESSMORE H WALENGA JM HOPPENSTEADT D FARID S WEHRMACHER W BERMES EW
Citation: E. Coyne et al., FISH SKIN GLYCOSAMINOGLYCANS - A SOURCE FOR HIGHLY-ACTIVE HEAVILY SULFATED CHONDROITIN SULFATES, Thrombosis and haemostasis, 73(6), 1995, pp. 1351-1351
PILOT-STUDY TO DETERMINE USE OF A TAS ANALYZER IN AN ANTICOAGULATION CLINIC SETTING
Authors: FABBRINI N MESSMORE H BALBALE S PANZA L EDWARDS B FLYNN C JOVE M COURNOYER C ACUNCIUS L BIRD ML CROSBY T BRACE L
Citation: N. Fabbrini et al., PILOT-STUDY TO DETERMINE USE OF A TAS ANALYZER IN AN ANTICOAGULATION CLINIC SETTING, Blood, 86(10), 1995, pp. 3463-3463
NEWER ANTICOAGULANTS FOR INTERVENTIONAL RADIOLOGIC PROCEDURES
Authors: IGBAL O MONCADA R HOPPENSTEADT D BREDDIN HK WALENGA JM FAREED J MESSMORE H
Citation: O. Igbal et al., NEWER ANTICOAGULANTS FOR INTERVENTIONAL RADIOLOGIC PROCEDURES, The FASEB journal, 8(5), 1994, pp. 10000641-10000641
LUPUS ANTICOAGULANT ASSAYS
Authors: MESSMORE H FABBRINI N HOPPENSTEADT D LARACH F FAREED J
Citation: H. Messmore et al., LUPUS ANTICOAGULANT ASSAYS, Seminars in thrombosis and hemostasis, 20(1), 1994, pp. 79-88
PROTHROMBIN TIME - PERFORMANCE-CHARACTERISTICS OF THE MORE SENSITIVE THROMBOPLASTIN REAGENTS
Authors: FABBRINI N HEMPHILL S BALBALE S MESSMORE H BRACE L LAY M PANZA L CROSBY T DILLON R
Citation: N. Fabbrini et al., PROTHROMBIN TIME - PERFORMANCE-CHARACTERISTICS OF THE MORE SENSITIVE THROMBOPLASTIN REAGENTS, Blood, 84(10), 1994, pp. 10000200-10000200
UNIQUE CIRCULATING ANTICOAGULANT IN A MYELOMA PATIENT WITH PROTEIN-C DEFICIENCY AND VENOUS THROMBOSIS
Authors: MESSMORE H FABBRINI N FARID S MORGAN J MCLEAN K YUEN B FAREED J BHOOPALAM N HOPPENSTEADT D
Citation: H. Messmore et al., UNIQUE CIRCULATING ANTICOAGULANT IN A MYELOMA PATIENT WITH PROTEIN-C DEFICIENCY AND VENOUS THROMBOSIS, Blood, 84(10), 1994, pp. 10000680-10000680
VALIDATION OF HEPTEST AND A MODIFIED (HEPTEST-HI) IN MONITORING THERAPEUTIC ANTICOAGULATION BY HEPARINS
Authors: FABBRINI N KOZA M HOPPENSTEADT D WALENGA JM FASANELLA A MESSMORE H FAREED J
Citation: N. Fabbrini et al., VALIDATION OF HEPTEST AND A MODIFIED (HEPTEST-HI) IN MONITORING THERAPEUTIC ANTICOAGULATION BY HEPARINS, Thrombosis and haemostasis, 69(6), 1993, pp. 1109-1109
MEDICAL AND SURGICAL USES OF RECOMBINANT HIRUDIN - AN INTERNATIONAL DISCUSSION FORUM MUNICH, GERMANY, JUNG 26, 1991
Authors: BACHER P MARKWARDT F MESSMORE H FAREED J WALENGA J HOPPENSTEADT D OFOSU F FINK E AMIRAL J FENTON J SAWYER R MARAGANORE J BREDDIN HK LEYA F HUBBARD T STEMBERGER A KAISER B ROSENKRANZ B KU C BUTTI A PIFARRE R
Citation: P. Bacher et al., MEDICAL AND SURGICAL USES OF RECOMBINANT HIRUDIN - AN INTERNATIONAL DISCUSSION FORUM MUNICH, GERMANY, JUNG 26, 1991, Seminars in thrombosis and hemostasis, 19, 1993, pp. 210-216
COMPARISON OF THE HEPTEST(R), HEPTEST HI(R) WITH THE ACTIVATED PARTIAL THROMBOPLASTIN TIME TO MONITOR LOW-MOLECULAR-WEIGHT HEPARIN-THERAPY
Authors: MESSMORE H FARID S FABBRINI N
Citation: H. Messmore et al., COMPARISON OF THE HEPTEST(R), HEPTEST HI(R) WITH THE ACTIVATED PARTIAL THROMBOPLASTIN TIME TO MONITOR LOW-MOLECULAR-WEIGHT HEPARIN-THERAPY, Blood, 82(10), 1993, pp. 10000597-10000597
RECOMBINANT TISSUE FACTOR AS A REAGENT FOR THE DETECTION OF THE LUPUSANTICOAGULANT
Authors: GODWIN JE HOPENSTEADT D BLAKEMORE C FARID S FAREED J MESSMORE H
Citation: Je. Godwin et al., RECOMBINANT TISSUE FACTOR AS A REAGENT FOR THE DETECTION OF THE LUPUSANTICOAGULANT, Blood, 82(10), 1993, pp. 10000617-10000617
MONITORING HEPARIN-THERAPY IN A PATIENT WITH THE LUPUS ANTICOAGULANT
Authors: MESSMORE H FARID S FABBRINI N
Citation: H. Messmore et al., MONITORING HEPARIN-THERAPY IN A PATIENT WITH THE LUPUS ANTICOAGULANT, Blood, 82(10), 1993, pp. 10000620-10000620
Risultati: 1-22 |